Reports Q1 Cash, cash equivalents, and marketable securities were $101.6M as of March 31, compared to $117.9M as of December 31. The Company expects its cash, cash equivalents and marketable securities to fund its operational plans into the second half of 2025..”During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our oral small molecule, through development and are well-positioned to deliver two value-driving data readouts from our clinical programs in 2024,” said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “These data will deliver important insights on TREM2 agonism in rare and common neurodegenerative diseases and will further support our commitment and mission to address the treatment needs for patients as quickly as possible.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP
- Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience’s Funding Peril: Navigating Market Turbulence in Equity Capital Raises
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Vigil Neuroscience sees cash runway into 2H25